Mirum Pharmaceuticals Inc
NASDAQ:MIRM
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
23.57
46.48
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Mirum Pharmaceuticals Inc
Mirum Pharmaceuticals Inc
Capital Expenditures
Mirum Pharmaceuticals Inc
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM
|
Capital Expenditures
-$20.1m
|
CAGR 3-Years
-344%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Capital Expenditures
-$888m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-4%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Capital Expenditures
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Capital Expenditures
-$974m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Capital Expenditures
-$508.9m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
-47%
|
CAGR 10-Years
-26%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Capital Expenditures
-$928.1m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
-13%
|
|
Mirum Pharmaceuticals Inc
Glance View
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Foster City, California and currently employs 137 full-time employees. The company went IPO on 2019-07-18. The firm is focused on the identification, acquisition, development, and commercialization of therapies for rare and orphan diseases. The firm's main focus is the development and commercialization of LIVMARLI (maralixibat) oral solution (Livmarli) and Volixibat. Its pipeline consists of rare pediatric indications for Livmarli and orphan adult indications for its second product candidate, Volixibat. Livmarli is an oral solution as a once-daily medicine for cholestatic pruritus in patients with Alagille syndrome (ALGS) one year of age and older. Volixibat, is an oral, minimally absorbed agent designed to inhibit ileal bile acid transporter (IBAT), for the treatment of adult patients with cholestatic liver diseases. The firm is developing volixibat for the treatment of intrahepatic cholestasis of pregnancy (ICP), primary sclerosing cholangitis (PSC), and primary biliary cholangitis (PBC).
See Also
What is Mirum Pharmaceuticals Inc's Capital Expenditures?
Capital Expenditures
-20.1m
USD
Based on the financial report for Dec 31, 2023, Mirum Pharmaceuticals Inc's Capital Expenditures amounts to -20.1m USD.
What is Mirum Pharmaceuticals Inc's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
-22%
Over the last year, the Capital Expenditures growth was -7 082%. The average annual Capital Expenditures growth rates for Mirum Pharmaceuticals Inc have been -344% over the past three years , -22% over the past five years .
You don't have any saved screeners yet
